ENGLEWOOD CLIFFS, N.J.--(BUSINESS WIRE)--Enzychem Lifesciences (KOSDAQ: 183490), a late-stage biopharmaceutical company, announced today the acceptance of a poster presentation at the Radiation Research Society (RRS) 2022 Annual Meeting, which will be held in Waikoloa, Hawaii on October 16-19, 2022.
ENGLEWOOD CLIFFS, N.J.--(BUSINESS WIRE)--Enzychem Lifesciences (KOSDAQ: 183490), a late-stage biopharmaceutical company, announced today that the abstract has been accepted for an Oral Proffered Paper at the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO) 2022 annual meeting, which will be held in hybrid on June 23-25, 2022 in Toronto, Canada.
ENGLEWOOD CLIFFS, N.J.--(BUSINESS WIRE)--Enzychem Lifesciences (KOSDAQ: 183490), a late-stage biopharmaceutical company, announced that it will present new Phase 2 US clinical study data regarding its lead drug candidate, EC-18 for chemoradiation-induced oral mucositis (CRIOM) at the American Society of Clinical Oncology (ASCO) 2022 annual meeting, which will be held in-person on June 3-7th, 2022 in Chicago.
ENGLEWOOD CLIFFS, N.J.--(BUSINESS WIRE)--Enzychem Lifesciences (KOSDAQ: 183490), a late-stage biotechnology company, announced today that the company has completed the final Clinical Study Report (CSR) for their Phase 2 study of EC-18 in Chemoradiation-induced Oral Mucositis (CRIOM), entitled “Phase 2, multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of EC-18 in altering the severity and course of oral mucositis (OM) in subjects being treated with concomitant chemoradiation therapy for cancers of the mouth, oropharynx, hypopharynx, and nasopharynx.”
ENGLEWOOD CLIFFS, N.J.--(BUSINESS WIRE)--Enzychem Lifesciences (KOSDAQ: 183490), a clinical-stage biotechnology company, announced today the formation of its Corporate Advisory Committee. Composed of four eminent physicians, its mission is to support and guide corporate activities including technology transfer for its lead compound, EC-18, seeking strategic partnerships, and preparing U.S. phase 3 clinical trials to successfully commercialize EC-18.
GOLDEN, Colo.--(BUSINESS WIRE)--PharmaJet®, the maker of innovative, needle-free injection technology, today announced that its partner Zydus Cadila, is partnering with Enzychem Lifesciences to manufacture their COVID-19 plasmid DNA vaccine (ZyCoV-D®) in Korea. The plan is to manufacture 80+ million doses of the ZyCoV-D vaccine, which was recently granted emergency use approval (EUA) by India’s national regulatory agency for those aged 12 years and above. The vaccine will be manufactured in Korea and exported to several lower-middle income countries in Latin America and Asian New Southern Policy member countries. It is exclusively delivered by the PharmaJet Tropis® Needle-free Injection System.
Enzychem Lifesciences and Cadila Healthcare, a Zydus Group unit, have nsigned an agreement to manufacture the first-ever Covid-19 plasmid ndeoxyribonucleic acid (DNA) vaccine, ZyCoV-D.
Cadila Healthcare has entered into an agreement with Enzychem nLifesciences for its plasmid DNA vaccine to prevent COVID-19, reported nlivemint.com.
BENGALURU, Nov 24 (Reuters) - South Korea's Enzychem Lifesciences (183490.KQ) would make at least 80 million doses of India's homegrown DNA COVID-19 vaccine from Cadila Healthcare (CADI.NS), the Indian drugmaker said on Wednesday.
Enzychem Lifesciences has reported that its lead candidate, EC-18, decreased the duration and occurrence of severe oral mucositis in a Phase II clinical trial in head and neck cancer patients.